SAN CARLOS, Calif., March 06, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that company management will participate and present at the following investors conferences in March:
Location: Boston Marriott Copley Place
Date/Time: Wednesday, March 13, at 8:00 a.m. EDT
A live and archived webcast of the presentation will be available by visiting the Investors section of Iovance Biotherapeutics' website at http://ir.iovance.com.
Location: 28 State Street
Date/time: Thursday, March 14, at 3:30 p.m. EDT
Location: The Westin New York Grand Central
Date/Time: Tuesday, March 19, at 8:00 a.m. EDT
A live and archived webcast of the presentation will be available by visiting the Investors section of Iovance Biotherapeutics' website at http://ir.iovance.com.
Location: The Metropolitan Club
Date/Time: Thursday, March 21, at 11:25 a.m. EDT
Location: The Ritz-Carlton Shanghai, Pudong
Date/Time: Thursday, March 28, at 9:00 a.m. China Standard Time (CST)
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics intends to commercialize autologous cell therapy using tumor-infiltrating lymphocyte (TIL) technology that amplifies the body’s own immune response to eradicate solid tumors or attack blood cancers. The company’s lead candidates are being investigated for the treatment of patients with locally advanced, recurrent or metastatic cancers including melanoma and cervical, head and neck, and non-small cell lung cancer. For more information, please visit www.iovance.com.
Investor Relations Contacts:
Annie Chang
Solebury Trout
646-378-2972
achang@troutgroup.com
Chad Rubin
Solebury Trout
646-378-2947
crubin@troutgroup.com
Media Relations Contact:
Rich Allan
Solebury Trout
646-378-2958
rallan@troutgroup.com